Association Between High Sensitivity Troponin Levels Following Pediatric Orthotopic Heart Transplantation and Intensive Care Unit Resource Utilization
© 2024. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature..
The utility of troponin levels, including high sensitivity troponin T (hs-TnT), after orthotopic heart transplant (OHT) is controversial. Conflicting data exist regarding its use as a marker of acute rejection. Few studies have examined possible associations of hs-TnT levels immediately after OHT with metrics of intensive care unit (ICU) resource utilization or risk of acute rejection. We performed a retrospective cohort chart review including all OHT recipients < 20 years of age at our center between June 2019 and December 2022. Patients were divided into two groups based on supra- or sub-median initial hs-TnT levels (median 3462.5 ng/L). Primary outcome was days requiring ICU-level care, secondary outcomes included days intubated, days requiring positive pressure ventilation (PPV), days on inotropic medications, actual ICU length of stay, Vasoactive Inotrope Scores (VIS) on postoperative days (POD) 0 through 7, and acute rejection at 30 days and one year after OHT. Patients with higher hs-TnT required ICU level care for longer [13.5 (10-17.5) vs. 9.5 (8-12) days, p = 0.01] and spent more days intubated [6 (4-7) vs. 3 (3-5) days, p < 0.001], on PPV [9 (6-15) vs. 6 (5-8.5) days, p = 0.02], and on inotropes [11 (9-14) vs. 8 (7-11) days, p = 0.025]. VIS was only different between groups on POD7 [5 (3-7) vs. 3 (0-5), p = 0.04]. There was no difference in rejection between the groups. Higher hs-TnT immediately following pediatric OHT may predict higher ICU resource utilization, despite no difference in VIS, although it does not predict acute rejection in the first year after OHT.
Medienart: |
E-Artikel |
---|
Erscheinungsjahr: |
2024 |
---|---|
Erschienen: |
2024 |
Enthalten in: |
Zur Gesamtaufnahme - volume:45 |
---|---|
Enthalten in: |
Pediatric cardiology - 45(2024), 4 vom: 29. März, Seite 829-839 |
Sprache: |
Englisch |
---|
Beteiligte Personen: |
Butensky, Adam M [VerfasserIn] |
---|
Links: |
---|
Themen: |
Biomarkers |
---|
Anmerkungen: |
Date Completed 25.03.2024 Date Revised 25.03.2024 published: Print-Electronic Citation Status MEDLINE |
---|
doi: |
10.1007/s00246-024-03424-w |
---|
funding: |
|
---|---|
Förderinstitution / Projekttitel: |
|
PPN (Katalog-ID): |
NLM36914208X |
---|
LEADER | 01000caa a22002652 4500 | ||
---|---|---|---|
001 | NLM36914208X | ||
003 | DE-627 | ||
005 | 20240325235016.0 | ||
007 | cr uuu---uuuuu | ||
008 | 240301s2024 xx |||||o 00| ||eng c | ||
024 | 7 | |a 10.1007/s00246-024-03424-w |2 doi | |
028 | 5 | 2 | |a pubmed24n1346.xml |
035 | |a (DE-627)NLM36914208X | ||
035 | |a (NLM)38424311 | ||
040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
041 | |a eng | ||
100 | 1 | |a Butensky, Adam M |e verfasserin |4 aut | |
245 | 1 | 0 | |a Association Between High Sensitivity Troponin Levels Following Pediatric Orthotopic Heart Transplantation and Intensive Care Unit Resource Utilization |
264 | 1 | |c 2024 | |
336 | |a Text |b txt |2 rdacontent | ||
337 | |a ƒaComputermedien |b c |2 rdamedia | ||
338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
500 | |a Date Completed 25.03.2024 | ||
500 | |a Date Revised 25.03.2024 | ||
500 | |a published: Print-Electronic | ||
500 | |a Citation Status MEDLINE | ||
520 | |a © 2024. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature. | ||
520 | |a The utility of troponin levels, including high sensitivity troponin T (hs-TnT), after orthotopic heart transplant (OHT) is controversial. Conflicting data exist regarding its use as a marker of acute rejection. Few studies have examined possible associations of hs-TnT levels immediately after OHT with metrics of intensive care unit (ICU) resource utilization or risk of acute rejection. We performed a retrospective cohort chart review including all OHT recipients < 20 years of age at our center between June 2019 and December 2022. Patients were divided into two groups based on supra- or sub-median initial hs-TnT levels (median 3462.5 ng/L). Primary outcome was days requiring ICU-level care, secondary outcomes included days intubated, days requiring positive pressure ventilation (PPV), days on inotropic medications, actual ICU length of stay, Vasoactive Inotrope Scores (VIS) on postoperative days (POD) 0 through 7, and acute rejection at 30 days and one year after OHT. Patients with higher hs-TnT required ICU level care for longer [13.5 (10-17.5) vs. 9.5 (8-12) days, p = 0.01] and spent more days intubated [6 (4-7) vs. 3 (3-5) days, p < 0.001], on PPV [9 (6-15) vs. 6 (5-8.5) days, p = 0.02], and on inotropes [11 (9-14) vs. 8 (7-11) days, p = 0.025]. VIS was only different between groups on POD7 [5 (3-7) vs. 3 (0-5), p = 0.04]. There was no difference in rejection between the groups. Higher hs-TnT immediately following pediatric OHT may predict higher ICU resource utilization, despite no difference in VIS, although it does not predict acute rejection in the first year after OHT | ||
650 | 4 | |a Journal Article | |
650 | 4 | |a Intensive care unit | |
650 | 4 | |a Orthotopic heart transplant | |
650 | 4 | |a Pediatric | |
650 | 4 | |a Resource utilization | |
650 | 4 | |a Troponin | |
650 | 7 | |a Troponin |2 NLM | |
650 | 7 | |a Troponin T |2 NLM | |
650 | 7 | |a Biomarkers |2 NLM | |
700 | 1 | |a Desai, Shyam |e verfasserin |4 aut | |
700 | 1 | |a Dilorenzo, Michael |e verfasserin |4 aut | |
700 | 1 | |a Lytrivi, Irene D |e verfasserin |4 aut | |
700 | 1 | |a Mantell, Benjamin S |e verfasserin |4 aut | |
700 | 1 | |a Zhang, Yun |e verfasserin |4 aut | |
700 | 1 | |a Choudhury, Tarif A |e verfasserin |4 aut | |
773 | 0 | 8 | |i Enthalten in |t Pediatric cardiology |d 1993 |g 45(2024), 4 vom: 29. März, Seite 829-839 |w (DE-627)NLM012996831 |x 1432-1971 |7 nnns |
773 | 1 | 8 | |g volume:45 |g year:2024 |g number:4 |g day:29 |g month:03 |g pages:829-839 |
856 | 4 | 0 | |u http://dx.doi.org/10.1007/s00246-024-03424-w |3 Volltext |
912 | |a GBV_USEFLAG_A | ||
912 | |a GBV_NLM | ||
951 | |a AR | ||
952 | |d 45 |j 2024 |e 4 |b 29 |c 03 |h 829-839 |